20 November 2024 - NICE has published final evidence-based recommendations on the use of fedratinib dihydrochloride monohydrate (Inrebic) for the treatment of adults with disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.

Fedratinib dihydrochloride monohydrate is recommended as an option for the treatment of adults with disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis only if:

• They have been treated with ruxolitinib phosphate
• The use of momelotinib dihydrochloride monohydrate is unsuitable
• BMS provides fedratinib dihydrochloride monohydrate according to the commercial arrangement

Read NICE technology appraisal guidance